Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - Prelude Therapeutics (NAS

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - Prelude Therapeutics (NAS

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the "Common Stock") at a price of $4.44 per share, and, in lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of it…